Charles River Laboratories International (NYSE:CRL) Releases FY25 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $9.10-$9.60 for the period, compared to the consensus estimate of $9.60. The company issued revenue guidance of $3.77-$3.87 billion, compared to the consensus revenue estimate of $3.87 billion. Charles River Laboratories International also updated its FY 2025 guidance to 9.100-9.600 EPS.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on CRL shares. JPMorgan Chase & Co. cut their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a report on Monday, February 3rd. Evercore ISI boosted their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a research note on Monday, November 18th. Morgan Stanley cut their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. Finally, William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $197.64.

Charles River Laboratories International Stock Performance

CRL stock traded up $10.61 during midday trading on Wednesday, hitting $165.00. The stock had a trading volume of 1,983,081 shares, compared to its average volume of 1,032,287. Charles River Laboratories International has a 52 week low of $150.79 and a 52 week high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock has a 50-day simple moving average of $174.59 and a 200 day simple moving average of $189.16. The firm has a market capitalization of $8.44 billion, a price-to-earnings ratio of 20.65, a P/E/G ratio of 5.91 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period last year, the firm earned $2.46 EPS. As a group, equities research analysts anticipate that Charles River Laboratories International will post 10.16 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).